Ahmi Ben-Yehudah

Title: Ahmi Ben-Yehudah: Innovator in Chimeric Proteins and Cancer Diagnosis

Introduction

Ahmi Ben-Yehudah is a notable inventor based in D.N. Harpi Yehuda, Israel. He has made significant contributions to the field of biotechnology, particularly in the development of chimeric proteins and methods for cancer diagnosis. With a total of 2 patents, his work has the potential to impact cancer treatment and diagnostics.

Latest Patents

Ben-Yehudah's latest patents include innovative inventions that focus on chimeric proteins with cell-targeting specificity and apoptosis-inducing activities. The first patent describes a recombinant chimeric protein that combines human interleukin-2 (IL2) and Bax. This chimeric protein is designed to specifically target IL2 receptor (IL2R)-expressing cells, inducing cell-specific apoptosis. The second patent outlines methods for cancer diagnosis using a chimeric toxin. This invention utilizes a chimeric toxin composed of gonadotropin-releasing hormone (GnRH) and Pseudomonas exotoxin A (PE) to detect tumor-associated epitopes expressed by human adenocarcinomas. The patent exemplifies mutated GnRH-PE molecules that bind to tumor cells without killing them.

Career Highlights

Throughout his career, Ahmi Ben-Yehudah has worked with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. His work at this esteemed institution has allowed him to further his research and contribute to advancements in biotechnology.

Collaborations

Ben-Yehudah has collaborated with notable colleagues such as Shai Yarkoni and Haya Lorberboum-Galski. These collaborations have enriched his research and expanded the impact of his inventions.

Conclusion

Ahmi Ben-Yehudah is a distinguished inventor whose work in chimeric proteins and cancer diagnostics showcases his innovative spirit and dedication to advancing medical science. His contributions are poised to make a significant difference in the field of cancer treatment and diagnosis.